Pfizer Buys Stake in French Lyme Disease Jab Partner
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.
There is currently no available vaccine for Lyme disease, the tick-borne infection that, while rarely fatal, can leave patients with debilitating side effects for months. But now that's a matter of a ticking clock.
On Monday, Pfizer took a $95 million, 8.1% stake in French vaccine developer Valneva to reset the terms of an alliance to develop the first Lyme disease shot in two decades.
Source Fool.com
